MSN and Dyskinesia: Taken together, these observations suggest that while D1-MSN activation is necessary for both the therapeutic effects of levodopa and the expression of dyskinesia, the behavioral outcome at comparable levels of D1-MSN activity appears to be shaped by D2-MSNs: their suppression promotes LID, while their co-activation supports therapeutic locomotion.